Adverum Biotechnologies Inc (ADVM)

O firmie

Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company targeting unmet medical needs for serious ocular and rare diseases. The Company is evaluating its gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of its lead indication, wet age-related macular degeneration. It has collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize gene therapy products (AVA-311) for ophthalmic diseases. The Company develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its capabilities include clinical development, vector discovery, and in-house manufacturing, specifically in process development, assay development and current Good Manufacturing Practices (cGMP) quality control.